Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $18 from $19 and keeps an Outperform rating on the shares. The firm ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

Fintel reports that on March 25, 2025, Leerink Partners downgraded their outlook for Opthea Limited - Depositary Receipt () (NasdaqGS:OPT) from Outperform to Market Perform. Analyst Price Forecast ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP – Free Report) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating ...

Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...

But the deal amount still came 41% below Leerink Partners’ $487 million valuation for 2seventy based on the biotech’s expected future cash flows. Before ending its coverage of 2seventy at the ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph ...

will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. A live webcast will be available on the Alumis website in the ...

Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida. Adagene Inc ...